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Abstract
Background: We have demonstrated that growth differentiation factor 9 (GDF9) enhances activin A-induced inhibin bB-
subunit mRNA levels in human granulosa-lutein (hGL) cells by regulating receptors and key intracellular components of the
activin signaling pathway. However, we could not exclude its effects on follistatin (FST) and follistatin-like 3 (FSTL3), well
recognized extracellular inhibitors of activin A.
Methodology: hGL cells from women undergoing in vitro fertilization (IVF) treatment were cultured with and without siRNA
transfection of FST, FSTL3 or GDF9 and then treated with GDF9, activin A, FST, FSTL3 or combinations. FST, FSTL3 and
inhibin bB-subunit mRNA, and FST, FSTL3 and inhibin B protein levels were assessed with real-time RT-PCR and ELISA,
respectively. Data were log transformed before ANOVA followed by Tukey’s test.
Principal Findings: GDF9 suppressed basal FST and FSTL3 mRNA and protein levels in a time- and dose-dependent manner
and inhibited activin A-induced FST and FSTL3 mRNA and protein expression, effects attenuated by BMPR2 extracellular
domain (BMPR2 ECD), a GDF9 antagonist. After GDF9 siRNA transfection, basal and activin A-induced FST and FSTL3 mRNA
and protein levels increased, but changes were reversed by adding GDF9. Reduced endogenous FST or FSTL3 expression
with corresponding siRNA transfection augmented activin A-induced inhibin bB-subunit mRNA levels as well as inhibin B
levels (P values all ,0.05). Furthermore, the enhancing effects of GDF9 in activin A-induced inhibin bB-subunit mRNA and
inhibin B production were attenuated by adding FST.
Conclusion: GDF9 decreases basal and activin A-induced FST and FSTL3 expression, and this explains, in part, its enhancing
effects on activin A-induced inhibin bB-subunit mRNA expression and inhibin B production in hGL cells.
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Introduction
Inhibin and activin are structurally related dimeric glycoprotein
hormones that inhibit and stimulate, respectively, the secretion of
FSH by pituitary gonadotrophs. Inhibin A and B are dimers of a
common a-subunit covalently coupled to bA-o rbB-subunit,
respectively. Activins are dimers of the b-subunits: activin A
(bAbA), activin B (bBbB), and activin AB (bAbB).
Activin has putative biological actions in a wide variety of tissues
such as the pituitary, bone, gonad, liver, and kidney as well as
hematopoeitic cells (see Ref. [1,2]). Activin signaling is regulated
by a number of extracellular and intracellular mechanisms [3].
Among the extracellular regulators are some members of the
follistatin (FST)-related protein family. This family consists of a
large group of proteins which contain a highly conserved module
of cysteine-rich sequence termed the follistatin domain and
includes follistatin [4], follistatin-like (FSTL) proteins such as
FSTL3 [5], and agrin [6]. Apart from follistatin and FSTL3
{formerly known as FST-related protein (FSRP) and FST-related
gene (FLRG)} which are major regulators of activin action, most
proteins in this family do not have this follistatin-like activity. Like
follistatin, FSTL3 binds activin with high affinity and prevents
activin from binding to its receptors, and hence, neutralizes activin
biological activities [7,8].
GDF9 was first discovered in 1993 and identified as a member
of TGFb superfamily [9]. In most mammalian species, GDF9 is
expressed predominantly in the growing oocytes from the primary
follicle stage onwards until fertilization and plays important roles
during follicle development [10–15]. Although GDF9 and activin
A bind to different receptors, both activate the Smad signaling
pathway (Smad 2/3/4/7) downstream. We have recently reported
[16,17] that exogenous and endogenous GDF9 can significantly
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inducing activin receptors (ACVR2B/1B) and Smad2/3 but
reducing Smad7 (an inhibitory Smad) mRNA levels in human
granulosa-lutein (hGL) cells. We have also confirmed GDF9
expression in hGL cells [17]. However, its effects on extracellular
regulators of activin such as FST and FSTL3 remain unknown.
Activin A can promote FST production in undifferentiated and
partially differentiated rat granulosa cells, but suppress FST
production in fully differentiated granulosa cells [18]. Activin A
can cause a 1.8-fold rise in FST release in rat anterior pituitary
cells, suggesting an autocrine/paracrine role of activin and FST in
the pituitary [19]. Activin A can also increase FST and FSTL3
mRNA and protein levels in the human hepatoma cell line HepG2
[20] but whether the same occurs in human granulosa cells is
unknown. The objectives of the present work were to examine the
effects of GDF9 on FST and FSTL3 expression, with and without
activin A treatment, as potential mechanisms on its enhancing
action on activin A-induced inhibin bB-subunit mRNA expression
and inhibin B production in hGL cells. Because FST has two
isoforms, FST288 and FST315, we also compared the effects of
these isoforms on the actions of activin A.
Materials and Methods
Firstly, we compared FST and FSTL3 mRNA in hGL cells and
protein in culture media with and without GDF9 treatment in
time- and dose-dependent experiments. Secondly, we explored the
effects of GDF9 on activin A-induced FST and FSTL3 mRNA
and protein levels. Thirdly, we transfected hGL cells with GDF9
siRNA to assess changes in basal and activin A-induced FST and
FSTL3 levels. Fourthly, we compared inhibin bB-subunit mRNA
levels after activin A treatment with and without FST or FSTL3
siRNA. Finally, to further evaluate if the enhancing effect of GDF9
on activin A-induced inhibin bB-subunit mRNA is related to FST
or FSTL3 expression, we measured these changes in activin A-
treated hGL cells (with and without GDF9) at different doses of
FST or FSTL3.
Preparation of hGL cells
The study was approved by the Research Ethics Board of the
University of British Columbia. hGL cells were obtained from
women undergoing in vitro fertilization treatment, and written
informed consent was obtained from all participants involved in
this study. For each patient, cells from multiple follicles and
consequently follicular fluid were pooled respectively. Granulosa
cells from each patient were extracted as described previously [16].
2610
5 viable cells were seeded per well in 12-well culture plates
and cultured in DMEM/F-12 (Sigma Chemical Co., St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS; HyClone
Laboratories, Logan, UT), 100 U/ml penicillin (GIBCO BRL Life
Technologies, Grand Island, NY), 100 mg/ml streptomycin
sulphate (GIBCO) and 1 6 GlutaMAX
TM (GIBCO) in a
humidified atmosphere of 5% CO2-95% air at 37 C for 48 h.
Activin A, GDF9, FST and FSTL3 experiments
After preculture of hGL cells for 48 h, the above medium
containing 0.5% FBS (‘‘low-serum media’’) instead of 10% FBS
was added to each well and the cell culture was now designated as
‘‘Time 0 h’’ for all subsequent experiments described below. The
experimental conditions, and the rationale for selecting the dose of
25 ng/ml of recombinant human activin A (Sigma) and 100 ng/
ml of recombinant human GDF9 (Peprotech Inc., Rocky Hill, NJ)
for our experiments were detailed in our recent publications
[16,17]. For time-dependent experiments, cells were treated with
the dose of 100 ng/ml of GDF9 for 12, 24 and 48 h. Cells were
stimulated with 1–200 ng/ml of GDF9 for 24 h in dose-response
studies. For experiments with both GDF9 and activin A, cells were
preincubated with 100 ng/ml of GDF9 in low-serum media for
24 h before stimulation with 25 ng/ml of activin A. In
neutralization experiments to render GDF9 inactive, 2 mg/ml of
recombinant extracellular domain (ECD) fused to the Fc region of
human IgG (receptor-ECD/Fc chimera) of human BMP receptor-
2 (BMPR2 ECD, a GDF9 antagonist; R&D Systems, Minneapolis,
MN) and 100 ng/ml of GDF9 were preincubated in low-serum
media for 30 min before adding to cultured hGL cells. To test the
effects of FST or FSTL3 on activin A-induced inhibin bB-subunit
mRNA expression, different doses of each of the two recombinant
human FST isoforms, 288-amino acid FST (FST288; Peprotech)
and 315-amino acid FST (FST315; R&D Systems), or FSTL3
(R&D Systems) were preincubated with 25 ng/ml activin A at 37
C for 1 h in PBS containing 0.1% BSA before adding to hGL cells
which were then cultured for 24 h.
Knockdown analysis for human GDF9, FST or FSTL3
We performed transient knockdown assays with 80 nM of
GDF9, FST or FSTL3 siRNA using non-targeting siRNA (ON-
TARGETplus SMARTpool; Dharmacon Research, Inc., Lafay-
ette, CO) as control. After pre-culture of hGL cells for 48 h, the
media were replaced with fresh antibiotics-free culture media, and
non-targeting siRNA (‘‘Control siRNA’’), GDF9 siRNA, FST
siRNA or FSTL3 siRNA was then added with Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) to the culture media. The
cell culture, immediately after adding transfection reagents, was
now designated as ‘‘Time 0 h’’ for all subsequent experiments
described below. After 24 h (‘‘Time 24 h’’), the spent media were
replaced with fresh antibiotic-free culture media to remove the
transfection reagents and the hGL cells were cultured for another
24 hours (‘‘Time 48 h’’). The spent media were then replaced with
low-serum media and hGL cells were further cultured for 24 h
(‘‘Time 72 h’’). mRNA levels of FST or FSTL3 were then
quantified with real-time PCR at 48 and 72 h after adding the
transfection reagents. Corresponding protein levels were quanti-
fied with ELISA at 72 h after siRNA transfection. In separate
experiments, the spent media at ‘‘Time 48 h’’ were replaced with
low-serum media and hGL cells were incubated with and without
100 ng/ml GDF9 for one more day (‘‘Time 72 h’’), and FST or
FSTL3 mRNA in cells and protein levels in culture media were
quantified with real-time PCR and ELISA respectively.
RNA extraction and Real-time RT-PCR
At the end of the treatment period, RNA was extracted from
hGL cells using TRIzol (Invitrogen). The experimental procedures
for RNA extraction, first-strand cDNA synthesis and SYBR Green
real-time PCR have been detailed in our recent publication [16].
The primers used for SYBR Green real-time PCR were designed
using the Primer Express Software (Applied Biosystems, Foster
City, CA) (Table 1) and tested with the intron spanning assay.
Expression levels of the interested genes were quantified and
normalized to those of the human housekeeping gene, GAPDH.
Changes after treatments were recorded as fold differences from
values in untreated controls at each time point as appropriate.
FST, FSTL3 and inhibin B assays
After treatment, culture media were collected and stored frozen
until assay with specific ELISA kits (FST, Peprotech; FSTL3,
R&D Systems; inhibin B, Diagnostic Systems Laboratories,
Webster, TX); corresponding hGL cells were lysed with lysis
buffer, and total cellular protein content determined as described
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B were 23, 312.5 and 7 pg/ml, respectively. The corresponding
intraassay coefficients of variation were 2.36, 1.92 and 3.5%; the
interassay coefficients of variation were 2.74, 2.12 and 6.20%. All
hormone measurements were performed in duplicate. Secreted
hormone levels were normalized to total cellular protein content.
Statistical analysis
Results were the means 6 SEM from at least four sets of
replicated experiments (each from a separate patient), and in each
set, measurements were made in triplicate for real-time PCR or
duplicate for ELISA. Data were log transformed and analyzed by
one-way ANOVA followed by Tukey’s multiple comparison tests if
the overall P values were significant at P,0.05 using PRISM
software (GraphPad Software, Inc., San Diego, CA).
Results
Effects of GDF9 on FST and FSTL3 mRNA and protein
levels
GDF9 significantly decreased FST and FSTL3 mRNA levels in
a time-dependent manner with maximum effects at 48 h (Figure 1,
A and B). GDF9 also reduced mRNA levels of FST and FSTL3 in
a dose-dependent manner which reached statistical significance at
both the 100 and 200 ng/ml doses (P values all ,0.01) (Figure 1,
C and D). BMPR2 is the type 2 receptor for GDF9 and the ECD
of BMPR2 is a well known GDF9 antagonist [16,17,21–23]. When
100 ng/ml of GDF9 was preincubated with BMPR2 ECD for
30 min before adding to the cell culture, the inhibitory effects of
GDF9 on FST and FSTL3 mRNA levels were attenuated
(Figure 1, C and D). Correspondingly, GDF9 decreased FST
and FSTL3 protein levels in a dose-dependent manner and
reached statistical significance at the 100 ng/ml dose (Figure 1, E
and F; P values all ,0.05); as a result, no significant decreases were
observed when GDF9 was first neutralized with BMPR2 ECD
(Figure 1E and F). As expected, there were no significant changes
in FST and FSTL3 mRNA levels relative to controls when
BMPR2 ECD alone was added. Basal protein levels of FST in
culture media were higher than those of FSTL3 (Figure 1, E and
F, 4450 vs. 548 pg/ml); correspondingly, the percentage decreases
in FST protein levels following GDF9 treatment were greater than
those of FSTL3 (32.4% vs. 24.8% at the GDF9 dose of 200 ng/ml;
P value ,0.001).
Effects of GDF9 on activin A-induced FST and FSTL3
mRNA and protein levels
Activin A increased both FST and FSTL3 mRNA levels
(Figure 2A; P values all ,0.001). In contrast, GDF9 suppressed
basal and activin A-induced FST and FSTL3 mRNA levels, effects
that were attenuated by BMPR2 ECD (Figure 2A; P values all
,0.05). As noted earlier, BMPR2 ECD alone had no effects on
FST and FSTL3 mRNA levels. Changes in FST and FSTL3
protein levels in culture media followed an identical pattern to
changes in mRNA levels (Figure 2B). However, FST mRNA levels
peaked at 12 h while those of FSTL3 peaked at 24 h in response to
activin A or activin A with GDF9 (Figure 2A).
Effects of GDF9-targeting siRNA transfection on activin
A-induced FST and FSTL3 mRNA and protein levels
When endogenous GDF9 levels decreased following GDF9
siRNA transfection (75% suppression of GDF9 mRNA level at
48 h, see Figure 1B of Ref. [17] for details), there were significant
increases in mRNA levels of FST and FSTL3 at 60 h and 72 h,
corresponding to ‘‘Time 12 h’’ and ‘‘Time 24 h’’ after activin A
treatment respectively as shown in Figure 3A (P values all ,0.001),
and corresponding proteins levels (Figure 3B; P values all ,0.001).
Furthermore, these effects of GDF9 siRNA were attenuated at 36
and 48 h after 100 ng/ml GDF9 was added to the culture
(corresponding to ‘‘Time 12 h’’ and ‘‘Time 24 h’’ after activin A
treatment in Figure 3). As a comparison, transfection with control
siRNA showed no changes relative to transfection reagent alone
(‘‘RNAiMAX’’). GDF9 siRNA transfection increased both basal
and activin A-induced FST mRNA levels at 12 h (P values all
,0.05) and 24 h in hGL cells (Figure 3A, upper panel), and basal
and activin A-induced FSTL3 mRNA at 12 and 24 h (Figure 3A,
lower panel), effects that were attenuated when cells were pre-
treated with 100 ng/ml GDF9 which reached statistical signifi-
cance at 12 h after activin A treatment for FST mRNA (P value
,0.05); and at both 12 h and 24 h after activin A treatment for
FSTL3 mRNA (P values all ,0.05 for both time points).
Corresponding changes in protein concentrations of FST and
FSTL3 in the culture media showed a similar pattern to mRNA
levels (Figure 3B).
FST- or FSTL3-targeting siRNA enhanced activin
A-induced inhibin bB-subunit mRNA and inhibin
B protein levels
As shown in Figure 4A, FST siRNA was specific for FST and
had no effects on FSTL3 mRNA and protein levels; similarly,
FSTL3 siRNA was specific for FSTL3 and had no effects on FST
mRNA and protein levels. As expected, control siRNA had no
effect on the basal inhibin bB-subunit mRNA levels; in addition, in
the absence of activin A treatment, GDF9-, FST- or FSTL3-
targeting siRNA had no effect on the basal inhibin bB-subunit
mRNA levels (Figure 4B, left panel). In contrast, in the presence of
activin A and consistent with our previous study [17], GDF9
treatment increased while GDF9 siRNA transfection decreased
inhibin bB-subunit mRNA levels (Figure 4B, left panel; P values all
,0.05). With reduced endogenous FST or FSTL3 expression after
targeting siRNA transfection (Figure 4A; P values all ,0.001 at
48 h), activin A-induced inhibin bB-subunit mRNA levels
increased from 15.7 fold for control siRNA to 27.7 fold for FST
Table 1. Nucleotide sequences of primers used for quantitative real-time PCR.
Gene Forward primer sequence Reverse primer sequence
FST 59-TGCTCTGCCAGTTCATGG-39 59-CTTGACGGAGCCAGCAGT-39
FSTL3 59-CTACATCTCCTCGTGCCACA-39 59-TCTTCTGCAGACTCACCACCT-39
Inhibin bB-subunit 59-ATCAGCTTCGCCGAGACA-39 59-GCCTTCGTTGGAGATGAAGA-39
GAPDH 59-ATGGAAATCCCATCACCATCTT-39 59-CGCCCCACTTGATTTTGG-39
doi:10.1371/journal.pone.0022866.t001
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(Figure 4B, left panel; P values all ,0.05). Corresponding changes in
inhibin B productions were similarly observed (Figure 4B, right
panel).
FST or FSTL3 reversed the effects of GDF9 on activin
A-induced inhibin bB-subunit mRNA and inhibin
B protein levels
To determine if GDF9 enhanced activin A-induced inhibin bB-
subunit mRNA levels by reducing FST or FSTL3 expression, we
compared these changes in the presence of different doses of
FST288, FST315 or FSTL3. We chose FST288 or FST315 doses
of 1, 2, 4 and 50 ng/ml and FSTL3 doses of 0.1, 0.2, 0.4, 4 and
50 ng/ml based on changes in FST and FSTL3 protein levels
following GDF9 treatment (Figure 1, E and F) and that FST or
FSTL3 binds to activin in a 2:1 molar ratio [24–27]. Increasing
doses of FST288 (1–4 ng/ml), FST315 (1–4 ng/ml) or FSTL3
(0.1–0.4 ng/ml) attenuated activin A-induced inhibin bB-subunit
mRNA levels with levels completely suppressed to those of activin
A treatment alone at the saturated dose of 50 ng/ml for both FST
isoforms and FSTL3 (Figure 5A). In the presence of GDF9,
inhibin bB-subunit mRNA levels decreased in a dose-dependent
manner for FST288, FST315, or FSTL3 (Figure 5A). Corre-
sponding changes in inhibin B production were likewise observed
(Figure 5B). While the suppressive effects of FST315 on activin A
Figure 1. Effects of GDF9 on FST and FSTL3 mRNA and protein levels. After 48 h preculture, the culture media were replaced with low-
serum media (0.5% FBS); hGL cells were then treated with 100 ng/ml GDF9 for 12 h (‘‘Time 12 h’’), 24 h (‘‘Time 24 h’’) and 48 h (‘‘Time 48 h’’) in time-
dependent experiments (A and B), or with different doses of GDF9 for 24 h in dose-dependent experiments (C, D, E and F). In neutralization
experiments to render GDF9 inactive, 2 mg/ml of BMPR2 ECD (‘‘ECD’’) and 100 ng/ml of GDF9 were preincubated in low-serum media for 30 min
before adding to cultured hGL cells. FST and FSTL3 mRNA levels (A, B, C and D) in hGL cells and protein concentrations (E and F) in culture media
were assessed by real-time PCR and ELISA, respectively. Results were the means 6 SEM from at least four sets of experiments (each from a separate
patient), and in each set, measurements were made in triplicate for real-time PCR or duplicate for ELISA. Means without a common letter are
significantly different (P,0.05).
doi:10.1371/journal.pone.0022866.g001
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below the saturated dose of 50 ng/ml, differences did not reach
statistical significance (Figure 5).
Discussion
We have recently reported that exogenous and endogenous
GDF9 enhances activin A-induced expression of inhibin bB-
subunit mRNA and inhibin B in hGL cells through modulation of
activin receptors and key components of the intracellular signaling
pathway [16,17]. Using the same hGL cell culture system in our
current study, we have demonstrated for the first time that GDF9
can decrease not only basal but also activin A-induced mRNA and
protein levels of FST and FSTL3, known extracellular inhibitors of
activin [7,28]. These actions of GDF9 were supported by our
experiments when GDF9 effects were neutralized by BMPR2
ECD or when endogenous GDF9 levels were reduced by targeting
siRNA transfection. We therefore hypothesize that GDF9
decreases FST or FSTL3 expression which allows more activin
A to bind to its receptors and hence, enhances activin A-induced
inhibin bB-subunit mRNA levels. Our hypothesis is further
supported by results from two additional experimental approach-
es. First, reduced endogenous FST or FSTL3 mRNA and protein
levels, after targeting siRNA transfection, augmented activin A-
induced inhibin bB-subunit mRNA levels similar to those observed
with GDF9 treatment (Figure 4B). Second, the enhancing effects
of GDF9 on activin A-induced inhibin bB-subunit mRNA and
inhibin B levels were attenuated by exogenous FST (both 288 and
315 isoforms) or FSTL3 in a dose-dependent manner (Figure 5).
Alternative precursor mRNA splicing produces two main
isoforms of mature mammalian follistatin, a core protein of 315
amino acids (FST315) and a carboxy-truncated variant of 288
amino acids (FST288) [29–31]. Although both isoforms have a
similar binding affinity for activin [32], FST288 also has a high
affinity for heparin [32,33]. In rat pituitary cells, complexes of
activin and FST288 bind to cell surface proteoglycans via the
heparin binding site of FST288 and is a mechanism by which
activin is targeted for degradation [34]. Although FST315 has the
same affinity for activin as FST288, it is primarily present in the
human circulation [35] and does not bind to heparin. Instead,
FST315 acts as a storage for follistatin in the circulation, which
delivers activin to target cells and prevents activin from binding to
FST288, and hence, degradation. Using TaqMan gene expression
assay with probes that could distinguish these two FST isoforms
(FST288 and FST315, Assay ID: Hs00246260_m1 and
Hs01121164_m1, respectively, Applied Biosystems, Foster City,
CA), we confirmed that GDF9 suppressed both isoforms in a time-
dependent manner (See Experimental Procedures S1 and Figure
S1, published on PLoS ONE online web site at http://www.
plosone.org/). In addition, the basal mRNA levels of FST315 were
Figure 2. GDF9 reversed activin A-induced FST and FSTL3 expression, effects attenuated by BMPR2 ECD. After 48 h preculture, hGL
cells were incubated in low-serum media (0.5% FBS) with and without 100 ng/ml of GDF9 for another 24 h before stimulation with 25 ng/ml of
activin A for 12 h (‘‘Time 12 h’’) and 24 h (‘‘Time 24 h’’). The neutralization experiments with BMPR2 ECD (‘‘ECD’’) and GDF9 were as described in
Figure 1. FST and FSTL3 mRNA levels (A) in hGL cells and protein concentrations (B) in culture media were assessed by real-time PCR and ELISA,
respectively. Results were the means 6 SEM from at least four sets of experiments (each from a separate patient), and in each set, measurements
were made in triplicate for real-time PCR or duplicate for ELISA. At each time point, means without a common letter are significantly different (P,0.05).
doi:10.1371/journal.pone.0022866.g002
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was about 3 cycles earlier than that of FST288). These results
suggest that FST315 mRNA may play a more dominant role in
our human granulosa-lutein cell culture system and are consistent
with the overall trend of a greater suppression of inhibin bB
subunit and inhibin B levels by FST315 relative to that of FST288
at equivalent doses below the saturated dose of 50 ng/ml in our
results (Figure 5). The relative ratio of activin-free to activin-bound
FST is essential in determining the bioavailability of activin and
estimating the potential endocrine function of circulating FST but
free follistatin assays are not commercially available at present.
Because FST binds activins and inhibins through the common b-
subunit [24], we cannot exclude the possibility that FST may also
interact with inhibins. However, FST has a 500 to 1000 fold
higher affinity for activins than inhibins [36].
FSTL3, which shares several structural features with FST, does
not have a heparin binding sequence and therefore, does not bind
cell-surface proteoglycans under normal conditions [37]. Isoforms
of FST are secreted faster than FSTL3 by stable, transfected CHO
cells and the amount of newly synthesized FSTL3 localized in the
nucleus is still substantial for up to 8 h, which is significantly longer
than that for FST [38]. This may explain partly why the protein
concentration of FST in the media of our cultured hGL cells was
about eight fold higher than that of FSTL3 (Figure 1, E and F,
4450 vs. 548 pg/ml, P,0.001). Despite a similar decrease in FST
or FSTL3 mRNA and protein levels 48 h after targeting siRNA
transfection (Figure 4A), activin A-induced inhibin bB-subunit
mRNA levels were higher following FST siRNA (Figure 4B;
P,0.05). Furthermore, at the same dose of 4 ng/ml, FST288 or
FST315 had a stronger effect than FSTL3 in suppressing activin
A-induced inhibin bB-subunit mRNA in the presence of GDF9
although these differences did not reach statistical significance
(Figure 5). Whether this indicates that FST may play a more
dominant role than FSTL3 in regulating activin A action requires
further studies.
FST protein levels were lower following FST siRNA transfec-
tion (from 4601 to 2544 pg/ml, Figure 5A, lower panel) than
treatment with 100 ng/ml of GDF9 (from 4451 to 3266 pg/ml,
Figure 1E), but corresponding activin A-induced inhibin bB-
subunit mRNA and inhibin B levels were lower after FST siRNA
transfection than GDF9 pre-treatment (Figure 4B). These
quantitative differences in activin A-induced inhibin bB-subunit
mRNA and inhibin B response may suggest that GDF9 acts
through not just the extracellular mechanism mediated by FST,
but as reported in our previous studies [16,17], the intracellular
mechanisms mediated by activin receptors and Smads. However,
Figure 3. GDF9-targeting siRNA increased activin A-induced FST and FSTL3 expression, effects reversed by GDF9 treatment. After
preculture for 48 h, hGL cells were transfected with 80 nM GDF9 targeting siRNA for 48 h. The culture media were then replaced by low-serum media
(0.5% FBS), and hGL cells were cultured with and without 100 ng/ml GDF9 for another 24 h period before stimulation with 25 ng/ml of activin A for
12 h (‘‘Time 12 h’’) and 24 h (‘‘Time 24 h’’). FST and FSTL3 mRNA levels (A) in hGL cells and protein concentrations (B) in culture media were assessed
by real-time PCR and ELISA, respectively. Results were the means 6 SEM from at least four sets of experiments (each from a separate patient), and in
each set, measurements were made in triplicate for real-time PCR or duplicate for ELISA. At each time point, means without a common letter are
significantly different (P,0.05).
doi:10.1371/journal.pone.0022866.g003
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22866Figure 4. GDF9-targeting siRNA attenuated while FST/FSTL3-targeting siRNA enhanced activin A-induced inhibin bB-subunit and
inhibin B expression. A: After preculture for 48 h, hGL cells were transfected with 80 nM of non targeting siRNA (‘‘Control siRNA’’) and FST- or
FSTL3-targeting siRNA for 24 h (‘‘Time 24 h’’) and 48 h (‘‘Time 48 h’’). FST and FSTL3 mRNA levels in hGL cells (upper panel) and protein
concentrations in culture media (lower panel) were assessed by real-time PCR and ELISA, respectively. Results were the means 6 SEM from at least
four sets of experiments (each from a separate patient), and in each set, measurements were made in triplicate for real-time PCR or duplicate for
ELISA. At each time point, means without a common letter are significantly different (P,0.05). B: After preculture for 48 h, hGL cells were transfected
with 80 nM of control siRNA and GDF9-, FST- or FSTL3-targeting siRNA for 48 h. The culture media were then replaced by low-serum media (0.5%
FBS), and hGL cells were cultured with and without 100 ng/ml GDF9 for another 24 h before treatment with 25 ng/ml activin A for 24 h. Inhibin bB-
subunit mRNA levels in hGL cells and inhibin B protein levels in culture media were measured by real-time PCR and ELISA respectively. Results were
the means 6 SEM from at least four sets of experiments (each from a separate patient), and in each set, measurements were made in triplicate for
real-time PCR and duplicate for ELISA. Means without a common letter are significantly different (P,0.05).
doi:10.1371/journal.pone.0022866.g004
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accounting for this difference. In addition, we also cannot rule out
the possibility that GDF9 may affect other extracellular inhibitors
of activin such as the BMP and activin membrane-bound inhibitor
(BAMBI). BAMBI is a transmembrane protein related to the
TGFb superfamily type I receptors. BAMBI lacks an intracellular
kinase domain but can block activin signaling by forming stable
associations with activin type IB receptor (ACVR1B, also known
as ALK4) but not activin type IA receptor (ACVR1A, also known
as ALK2) [39].
Serum levels of total and activin-free FST were about
10.161.6 ng/ml and 1 ng/ml respectively in normal cycling
women [40]. Thadhani et al. showed that women who developed
gestational diabetes mellitus had lower first-trimester serum levels
of FSTL3 compared with women who did not (median 10.789 vs.
30.670 ng/ml, P value ,0.001) [41]. The FST concentrations
used in our experiments did span the range observed under these
physiological states. However, the clinical significance of our
findings in normal physiology remains to be determined. In mouse
models, over-expression of FST has been shown to result in a
PCOS-like phenotype [42]. Higher FST levels observed in some
women with polycystic ovary syndrome (PCOS) have led to the
suggestion that altered FST function may contribute to the PCOS
phenotype [43]; however, an updated study on allelic variants of
the follistatin gene in PCOS suggests that the contribution of the
follistatin gene to the etiology of PCOS is small [44]. Decreased
GDF9 mRNA levels have been found in developing oocytes from
women with PCOS or polycystic ovaries compared to women with
normal ovaries; the decreased levels are evident throughout
folliculogenesis, beginning at recruitment initiation and continuing
Figure 5. GDF9 pretreatment enhanced activin A-induced inhibin bB-subunit and inhibin B expression, effects attenuated by FST/
FSTL3. After 48 h preculture, the culture media were replaced by low-serum media (0.5% FBS), and hGL cells were cultured with and without
100 ng/ml GDF9 for another 24 h in low-serum media. Different dose of FST288, FST315 or FSTL3 were preincubated with 25 ng activin A at 37 C for
1 h in 50 ml PBS containing 0.1% BSA before adding to the cells and cultured for another 24 h. Inhibin bB-subunit mRNA levels in hGL cells (A) and
inhibin B protein levels in culture media (B) were measured by real-time PCR and ELISA respectively. Results were the means 6 SEM from at least four
sets of experiments (each from a separate patient), and in each set, measurements were made in triplicate for real-time PCR and duplicate for ELISA.
Means without a common letter are significantly different (P,0.05).
doi:10.1371/journal.pone.0022866.g005
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FST or FSTL3 expression with decreased endogenous GDF9
levels after targeting siRNA transfection (Figure 3) may provide a
mechanism by which altered GDF9 expression can affect follicle
development, our granulosa cells were not specifically obtained
from women with PCOS. Future studies comparing the interac-
tions of FST or FSTL3 and GDF9 in granulosa cells from women
with and without PCOS may shed new insight on the
pathophysiology of this condition.
We have recently reported that inhibin B, with its production
enhanced by GDF9 pretreatment with activin A, can attenuate the
inhibitory effect of activin A on steroidogenic acute regulatory
protein [46] expression and progesterone production [47]. Activin
A is a known inhibitor of luteinization as reported in human
[48,49], bovine [50,51], and rat [52] ovaries. Serum free activin A
levels show little variation in the human menstrual cycle [53] while
serum inhibin B levels peak in the mid-follicular phase and
immediately following ovulation [54]. Based on these observations
and findings of our studies [16,17,47], we have previously
speculated that GDF9 may enhance activin A-induced inhibin B
production in the pre-ovulatory follicle sufficiently to overcome the
inhibitory effect of activin A on luteinization. Our current study
shows that GDF9 can also suppress mRNA and protein levels of
FST and FSTL3, known inhibitors of activin A actions, and
reverse their inhibitory effects on activin-induced inhibin B
production. This further corroborates our proposal for a potential
role of GDF9 in regulating activin A and inhibin B functions in
human granulsa cells during the follicular-luteal transition [49].
While our granulosa cell culture systems had provided a
convenient model to study the inter-relationships of FST or
FSTL3 and GDF9, these cells were exposed to pharmacological
doses of exogenous gonadotropins and were undergoing luteini-
zation following hCG administration. However, in the absence of
human granulosa cells from normal ovaries for research, findings
from our cell culture systems do provide interesting hypotheses on
the potential role of GDF9 in granulosa-lutein cell functions.
In summary, our previous studies suggest that GDF9 enhances
activin A-induced inhibin bB-subunit mRNA levels in hGL cells by
regulating receptors and crucial intracellular components of the
activin signaling pathway involving the Smad system [16,17]. Our
current study shows that GDF9 can decrease FST and FSTL3
expression in addition, which then allows more free activin A to
bind to its receptors and activate the signaling pathway
downstream. Taken together and as summarized in Figure 6,
GDF9 increases hGL cell response to activin A by acting on GDF9
receptors, BMPR2/TGFbR1, which then activate Smad2/3 to
form complexes with Smad4. These complexes then activate
transcription factors in the nucleus to target genes that increase
ACVR2B/1B and Smad2/3 expression and reduce Smad7
activity. These changes, in turn, allow more activin A to bind to
its receptors and increase the cellular response to accumulate
inhibin bB-subunit, and corresponding inhibin B levels intracellu-
Figure 6. A model on the interactions between GDF9, activin A, and FST/FSTL3 in regulating inhibin B production. GDF9 increases
hGL cell response to activin A by acting on GDF9 receptors, BMPR2/TGFbR1, which then activate Smad2/3 to form complexes with Smad4. These
complexes then activate transcription factors in the nucleus to target genes that increase ACVR2B/1B and Smad2/3 expression and reduce Smad7
activity [16,17]. These changes, in turn, allow more activin A to bind to its receptors and increase the cellular response to accumulate inhibin bB-
subunit, and corresponding inhibin B intracellularly. Additionally, GDF9 inhibits FST and FSTL3 gene transcription and FST and FSTL3 secretion
extracellularly, reducing the amount of FST and FSTL3 binding to activin A which then activates activin receptors and the downstream signaling
cascade and increases inhibin B accumulation. Abbreviations: ACVR, activin receptor; BMPR2, bone morphogenetic protein type II receptor; FST,
follistatin; FSTL3, follistatin-like 3; GDF9, growth differentiation factor 9; Smad, son of mothers against decapentaplegia; SBE, Smad binding element;
Co-Smad, common Smad; I-Smad, inhibitory Smad; R-Smad, receptor-activated Smad; TGFbR1, transforming growth factor b type I receptor.
doi:10.1371/journal.pone.0022866.g006
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extracellularly hence, the amount of activin A binding to FST and
FSTL3. More activin A can then interact with its receptors to
activate the downstream signaling cascade, leading to increased
inhibin B accumulation.
Although we have described the intracellular and extracellular
mechanisms as separate GDF9 actions, whether the extracellular
mechanism alone is sufficient to explain for the changes in the
intracellular pathway or whether GDF9 also has a separate
intracellular regulating role needs further research. Further
investigations will also be required to characterize the mechanism
on how GDF9 suppresses FST and FSTL3 expression, and
whether the Smad pathway is directly involved.
Supporting Information
Figure S1 Time-dependent effect of GDF9 on FST288
and FST315 mRNA levels. After 48 h preculture, the culture
media were replaced with low-serum media (0.5% FBS); hGL cells
were then treated with 100 ng/ml recombinant human GDF9 for
12 h (‘‘Time 12 h’’), 24 h (‘‘Time 24 h’’) and 48 h (‘‘Time 48 h’’)
in time-dependent experiments. FST288 and FST315 mRNA
levels in hGL cells were assessed by TaqMan Gene Expression
Assay. Results were the means 6 SEM from at least three sets of
experiments (each from a separate patient), and in each set,
measurements were made in triplicate. Means without a common letter
are significantly different (P,0.05).
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